介绍：Semaglutide-索马鲁肽，司美格鲁肽是人胰高血糖素样肽-1的一个长效类似物，是人胰高血糖素样肽-1 (GLP-1)受体的激动剂。Semaglutide有潜力用于2型糖尿病的研究。
链接：https://www.antibodysystem.com/product/17748.html
名称：Anti-Semaglutide (GLP-1 analogue) Polyclonal antibody抗体
别名：Sermaglutide, Semaglutide fandachem, Semaglutide impurity, Sermaglutide USP/EP/BP, semaglutide, Sermaglutide
货号：PHK13901
宿主：Rabbit
适用物种：Human
免疫原：Synthesized Semaglutide (GLP-1 analogue) conjugated with Carrier protein.
存储缓冲区：PBS, pH 7.4, containing 0.05% proclin 300, 50% glycerol.
形式：Liquid
浓度：1.28 mg/ml
克隆：Polyclonal
同型：IgG
应用：WB, IHC, ELISA
纯化：Antigen affinity purification.
内毒素水平：Please contact with the lab for this information.
CAS：910463-68-2
AntibodySystem是由法国专家团队创立的科研试剂品牌，产品管线覆盖各种病毒研究蛋白/抗体质控品、Invivo功能性抗体，流式抗休、抗药药物靶点蛋白以及其他活性蛋白、PEG抗体，磷酸化抗体、抗DNA抗体、小分子抗体、RUO ELISA试剂盒、生物类似物。
佰乐博生物：佰乐博生物代理antibodysystem品牌，是亚洲区运营总代理商
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
参考文献：
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. PMID: 33068776
GLP-1 receptor agonists and cardiovascular outcome trials: An update. PMID: 30528435
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. PMID: 38286487
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients. PMID: 34911560
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). PMID: 30944040
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. PMID: 34015974
Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. PMID: 32910487
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. PMID: 37952217
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. PMID: 38316982
Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. PMID: 38079178
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. PMID: 32987188
The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. PMID: 37684186
Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. PMID: 29915923
Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. PMID: 38113888
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? PMID: 30156747
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. PMID: 35838946
Liraglutide and obesity: a review of the data so far. PMID: 25848222
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure. PMID: 37409733
Semaglutide for the treatment of obesity. PMID: 34942372
Once-Weekly Semaglutide in Adolescents with Obesity. PMID: 36947474
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. PMID: 33667417
Wegovy (semaglutide): a new weight loss drug for chronic weight management. PMID: 34706925
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. PMID: 36578889
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. PMID: 33755728
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. PMID: 35015037
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. PMID: 37385278
Semaglutide lowers body weight in rodents via distributed neural pathways. PMID: 32213703
Semaglutide (Ozempic) for weight loss. PMID: 33830968
